Launch of the Africa CDC toolkit for hepatitis B: bringing care closer to people in Africa [0.03%]
非洲疾控中心推出乙肝工具包：让非洲的医疗服务更贴近民众
Alexander J Stockdale,Gibril Ndow,Danjuma Adda et al.
Alexander J Stockdale et al.
WHO global hepatitis report 2026: guiding global action for elimination [0.03%]
2026年世卫组织全球病毒性肝炎报告：指导全球行动实现消除目标
Olufunmilayo Lesi,Diana Faini,Irwin Law et al.
Olufunmilayo Lesi et al.
The glucagon and GLP-1 receptor dual agonist DD01 for metabolic dysfunction-associated steatotic liver disease and steatohepatitis (DD01-DN-02): 12-week results from a randomised, double-blind, multicentre, placebo-controlled, phase 2 trial [0.03%]
GLP-1和胰高血糖素受体双重激动剂DD01治疗与代谢紊乱相关的脂肪变性肝病和非酒精性 steatohepatitis（DD01-DN-02）：一项多中心、随机、双盲、安慰剂对照的2期试验12周结果
Mazen Noureddin,Winston Dunn,Rashmee Patil et al.
Mazen Noureddin et al.
Background: Metabolic dysfunction-associated steatohepatitis (MASH) is a major public health problem arising in the context of metabolic syndrome and obesity. DD01 is a liver-targeted GLP-1 receptor and glucagon dual agon...
Efficacy and safety of duvakitug in patients with ulcerative colitis (RELIEVE UCCD): a phase 2b, randomised, placebo-controlled trial [0.03%]
杜瓦克替冈治疗溃疡性结肠炎患者的疗效和安全性：一项2b期、随机、双盲、安慰剂对照试验（RELIEVE UCCD）
Walter Reinisch,David Stepek,Radoslaw Kempinski et al.
Walter Reinisch et al.
Background: Ulcerative colitis is a chronic inflammatory disease affecting the colon and rectum. We aimed to investigate the efficacy and safety of duvakitug, an anti-TNF-like cytokine 1A (TL1A) monoclonal antibody, in ad...
Efficacy and safety of duvakitug in patients with Crohn's disease (RELIEVE UCCD): a phase 2b, randomised, placebo-controlled trial [0.03%]
杜瓦克替冈治疗克罗恩病患者的疗效和安全性（RELIEVE-UCCD）：一项IIb期、随机、安慰剂对照试验
Vipul Jairath,Jaroslaw Kierkuś,George Aaron Duvall et al.
Vipul Jairath et al.
Background: Crohn's disease is a chronic, relapsing inflammatory disease of the gastrointestinal tract. We aimed to assess the efficacy and safety of duvakitug, an anti-TNF-like cytokine 1A monoclonal antibody, in adults ...
Yasmin Nasser,Andrea Shin,Alexander C Ford et al.
Yasmin Nasser et al.
Despite the continued absence of a definitive biomarker for irritable bowel syndrome (IBS), research over the last three decades has identified a wide range of underlying pathophysiological abnormalities. Peripheral mechanisms include gastr...
Artificial intelligence-assisted detection and optical differentiation of colorectal lesions in Lynch syndrome surveillance (CADLY2): a multicentre, open-label, randomised controlled superiority trial [0.03%]
人工智能辅助遗传性非息肉病性大肠癌监测中结直肠病变的检测和光学识别：多中心、开放标签、随机对照优效性试验
Robert Hüneburg,Querijn N E van Bokhorst,Maria Pellisé et al.
Robert Hüneburg et al.
Background: Artificial intelligence (AI)-based computer-aided detection (CADe) systems improve adenoma detection in average-risk colorectal cancer screening. Meanwhile, evidence in Lynch syndrome surveillance is sparse an...
Efficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2, dose-ranging, double-blind, randomised controlled trial [0.03%]
在代谢功能障碍相关性肝炎导致纤维化和肝硬化的受试者中，佐马杜林与司美格鲁肽联合给药的有效性和安全性：一项2期、剂量范围确定、双盲随机对照试验
Rohit Loomba,Jacob George,Laurent Castera et al.
Rohit Loomba et al.
Background: This phase 2 study evaluated once-weekly zalfermin and semaglutide for efficacy and safety in patients with metabolic dysfunction-associated steatohepatitis and clinically significant fibrosis, including patie...
Aspirin for cancer prevention in individuals with Lynch syndrome: first results from the CaPP3 multicentre, randomised, double-blind, non-inferiority trial [0.03%]
利什曼综合征个体的癌症预防性使用的阿司匹林：来自CaPP3多中心随机双盲非劣效性的试验第一结果
John Burn,Gillian M Borthwick,Faye Elliott et al.
John Burn et al.
Background: In CAPP2, 600 mg aspirin daily significantly reduced the incidence of colorectal cancer and the incidence of all Lynch syndrome cancers among participants with Lynch syndrome. CaPP3 aimed to assess the efficac...